Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Name
ijms-25-06733.pdf
Size
1.11 MB
Format
Adobe PDF
Checksum (MD5)
d9f2f5907cb0916885ed0c26af534bb5
Author(s)
Chang, Christopher
Chavarro, Velina S.
Gerstl, Jakob V. E.
Blitz, Sarah E.
Spanehl, Lennard
Dubinski, Daniel
Valdes, Pablo A.
Tran, Lily N.
Gupta, Saksham
Esposito, Luisa
Date Issued
June 19, 2024
Journal
International Journal of Molecular Sciences
Publisher
MDPI AG
Citation
Chang, C.; Chavarro, V.S.; Gerstl, J.V.E.; Blitz, S.E.; Spanehl, L.; Dubinski, D.; Valdes, P.A.; Tran, L.N.; Gupta, S.; Esposito, L.; et al. Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms. Int. J. Mol. Sci. 2024, 25, 6733.
Version
Final published version
Abstract
Glioblastoma is the most common and lethal central nervous system malignancy with a median survival after progression of only 6–9 months. Major biochemical mechanisms implicated in glioblastoma recurrence include aberrant molecular pathways, a recurrence-inducing tumor microenvironment, and epigenetic modifications. Contemporary standard-of-care (surgery, radiation, chemotherapy, and tumor treating fields) helps to control the primary tumor but rarely prevents relapse. Cytoreductive treatment such as surgery has shown benefits in recurrent glioblastoma; however, its use remains controversial. Several innovative treatments are emerging for recurrent glioblastoma, including checkpoint inhibitors, chimeric antigen receptor T cell therapy, oncolytic virotherapy, nanoparticle delivery, laser interstitial thermal therapy, and photodynamic therapy. This review seeks to provide readers with an overview of (1) recent discoveries in the molecular basis of recurrence; (2) the role of surgery in treating recurrence; and (3) novel treatment paradigms emerging for recurrent glioblastoma.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3390/ijms25126733
